However, a double-blind and randomised study (GOLD) failed to show a statistically significant benefit of olaparib combined with paclitaxel over paclitaxel alone in patients with advanced gastric cancer with low ATM protein expression, as assessed by IHC [42]. This evidence concerns the gene ATM and gastric cancer.